Sukumar Nagendran Taysha Gene Therapies, Inc. (TSHA) insider trading activity

Sukumar Nagendran is President and Head of R&D of Taysha Gene Therapies, Inc.. Currently has a direct ownership of 1.22 Million shares of TSHA, which is worth approximately $2.26 Million. The most recent transaction as insider was on Jan 02, 2025, when has been sold 324,500 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.22M

36.14% 3M change

36.14% 12M change

Total Value Held $2.26 Million

Sukumar Nagendran Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 02 2025	BUY Grant, award, or other acquisition	-	324,500 Added 20.98%	1,222,343 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	863,617 Added 49.03%	897,843 Common Stock
May 16 2023	BUY Open market or private purchase	$3,400 $0.68 p/Share	5,000 Added 12.75%	34,226 Common Stock
Feb 02 2022	BUY Open market or private purchase	$80,100 $8.01 p/Share	10,000 Added 25.49%	29,226 Common Stock
Sep 28 2020	BUY Conversion of derivative security	-	19,226 Added 50.0%	19,226 Common Stock

Also insider at

SLDB

Solid Biosciences Inc. Healthcare